March 2023: Peter MacCallum Cancer Center (Peter Mac) e-Australia kanye neCartherics Pty Ltd bangene esivumelwaneni sohlelo lokuthuthukisa ngokuhlanganyela (CDPA) sokuthuthukisa i-CTH-002 yokwelapha umdlavuza wesibeletho.
Ukuhlolwa komtholampilo okuzokwenziwa ngu-Peter Mac kuzoba ngokokuqala ngqa ukuthi kuhlolwe umkhiqizo we-CAR-T cell oqukethe ukuguqulwa kofuzo okufakwe ku-CTH-004 kubantu.
Umdlavuza we-Ovarian ungumdlavuza we-gynecological obulala kakhulu e-Australia, obulala abantu abangaphezu kwe-1,000 ngonyaka. Ngezinga lokusinda leminyaka emihlanu lama-49% kuphela, kunesidingo esiphuthumayo socwaningo ukuze kunikezwe labo abaxilongwa ithuba elingcono lokusinda.
Simon Harrison, umqondisi weCentre of Excellence in Cellular immunotherapy Peter Mac, wathi: “Ukwelashwa kwe-CAR-T-cell kuwukwelapha okunamandla okugonywa kwamasosha omzimba okuklanyelwe ngokukhethekile isiguli ngasinye futhi okuphinde kube nenjongo yama-T-cell aso ukulwa nomdlavuza waso.
“It has emerged as a new treatment paradigm in umdlavuza wegazi where it can produce complete responses, meaning their blood cancer has disappeared, in patients who have exhausted all other treatment options. The Centre of Excellence in Cellular Immunotherapy at Peter Mac is part of an international effort to expand Ukwelashwa kwe-CAR T-cell ngale komdlavuza wegazi, futhi siyajabula ukusebenzisana nabakwaCartherics kulolu cwaningo lomtholampilo lokuqala kubantu lomdlavuza wesibeletho.
Alan Trounson, CEO of Cartherics, said: “There are many patients needing help to control umdlavuza wesibeletho and CAR-T therapy could be a game changer for them. It is our priority to ensure this potential therapy is tested in izivivinyo zokwelashwa ngokushesha ngangokunokwenzeka."
Cartherics board advisor, Heather Hawkins said: “As an ovarian owasinda emdlavuza and patient advocate, I am truly grateful for the vision, skill and dedication of the Cartherics team who are working tirelessly – seeking to improve the survival rates and the quality of life of women diagnosed with ovarian cancer. This announcement brings a real sense of progress and hope in this space.”
Ngaphezu kuka-80% weziguli ezinomdlavuza wesibeletho eziqale zahlinzwa ngempumelelo futhi zelashwa ziphindela emuva.
Izinjongo eziyinhloko zocwaningo oluhlanganyelwe ukwenza i-CTH-004 esikalini somtholampilo kanye nokwenza uhlolo lomtholampilo lwesigaba I. Lolu hlelo luzoholwa yiCentre of Excellence in Cellular Immunotherapy ePeter Mac, kanti ukukhiqizwa kuzokwenziwa ozakwabo bokukhiqiza uPeter Mac, Cell Therapies Pty Ltd.
Ukuhlolwa komtholampilo kuzoqale kubhalise iziguli eziyisithupha kuya kweziyishumi nambili ezinomdlavuza wesibeletho okwelashwa kwazo kwangaphambili ngamakhemikhali ahlulekile. Inhloso eyinhloko yalolu cwaningo lomtholampilo ukuhlola ukuphepha kwe-CTH-004 kulesi sibalo seziguli.
UCartherics noPeter Mac basanda kumemezela ukusebenzisana kwe-CTH-001, omunye umkhiqizo ozenzakalelayo we-CAR-T owakhiwe ngabakwaCartherics. Abahlanganyeli bavumelene, ngokusekelwe kudatha ye-preclinical, ukuthi u-Peter Mac uzogxila emizamweni yakhe ku-CTH-004.
Mayelana nomdlavuza wesibeletho
I-Ovarian cancer is a disease in which abnormal cell growth in one or both ovaries leads to the development of cancer. Approximately 314,000 new ovarian cancer cases and 207,000 deaths occurred globally in 2020.
Ezigabeni zawo zokuqala, umdlavuza wesibeletho ngokuvamile awunazimpawu futhi uvame ukutholakala lapho sekuhambe isikhathi. Ukuhlinzwa kanye nokwelashwa ngamakhemikhali yizindlela zokwelapha ezivame kakhulu, kungaba zodwa noma zihlangene. Ngaphezu kuka-80% weziguli ezinomdlavuza wesibeletho eziqale zahlinzwa ngempumelelo futhi zelashwa ziphindela emuva.
Mayelana noPeter MacCallum Cancer Center
I-Peter MacCallum Cancer Center iyisikhungo socwaningo somdlavuza esisezingeni lomhlaba, sezemfundo, kanye nesezokwelapha, kanye nenkonzo yezempilo yomphakathi yase-Australia kuphela ezinikele ekunakekelweni komdlavuza. Lesi sikhungo siqashe abantu abangu-3,300, okuhlanganisa nabacwaningi baselabhorethri nabasemtholampilo abangaphezu kuka-750, bonke abazinikele ekuhlinzekeni ngemithi engcono yokwelapha umdlavuza, ukunakekelwa kanye nokwelapha okungenzeka.
I-Center of Excellence in Cellular Immunotherapy e-Peter Mac isekela, ithuthukise, futhi ihumushe izindlela zokwelapha zamaseli nezakhi zofuzo ezinoveli isebenzisa abahlinzeki bayo abasunguliwe kanye nozakwethu bokukhiqiza, njenge-Cell Therapies Pty Ltd, ukunika amandla ukusetshenziswa kwale mikhiqizo ezivivinyweni zomtholampilo zeziguli ezinomdlavuza.
Ukwengeza, inkampani idala i-autologous CAR-T cell zokwelapha. Lawa asebenzisa ama-T cell ashintshiwe avela kumasosha omzimba esiguli asebenza ngempumelelo ngokumelene namangqamuzana omdlavuza esiguli. I-CTH-004 ikhiqizwa ngokushintsha ufuzo amaseli T esiguli ukuze afake i-chimeric antigen receptor (CAR) ukuze iqondise umaka (TAG-72) kumaseli omdlavuza we-ovarian futhi isuse izakhi zofuzo ezihilelekile ekucindezelweni kokusebenza kwe-T cell.
Ukwelashwa kwe-CAR T-Cell eChina ikhule ngesivinini esikhulu, futhi njengamanje kunenhlolo yokwelashwa engaphezu kuka-750 eyenziwa eShayina ngezinhlobo ezahlukene zomdlavuza.
